The preclinical development of dual JAK2/BET inhibitors is ongoing with the goal of developing a single drug that can therapeutically target these critical proteins in MPN, potentially providing improved therapeutic efficacy with lower rates of drug resistance [113]. This evidence concerns the gene DNER and myeloproliferative disorder.